Accession Number:

ADA058221

Title:

Phase I Clinical Testing Antimalarial Drugs.

Descriptive Note:

Rept. no. 3 (Annual) Feb 77-Jan 78,

Corporate Author:

BIO-MED INC WASHINGTON DC

Personal Author(s):

Report Date:

1978-03-01

Pagination or Media Count:

47.0

Abstract:

The safety and tolerance of mefloquine 500 mg weekly over 52 weeks was determined in a study involving 50 subjects. A comprehensive study of the pharmacokinetics of mefloquine was also undertaken. Mefloquine methanesulfonate was shown to be unsafe when administered parenterally because of local tissue irritation. A concomitant decrease in serum haptoglobin was noted with infusion of this drug which is at present unexplained. A pharmacokinetics study of WR 184,806.H3PO4 involving 20 subjects was completed. A study to evaluate the gastrointestinal absorption kinetics of WR 30090 oleic acid was started but suspended pending the resolution of difficulties with the drug assay. A study to compare the bioavailability of the Walter Reed and Hoffmann-LaRoche formulations of mefloquine hydrochloride has just been completed. Author

Subject Categories:

  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE